Sevoflurane veterinary-grade API intended for vapor-delivered anaesthesia in companion animal surgery is released as a 100% w/w volatile liquid for filling into vapour-tight primary glass containers. The terminal solution form for small animal practice is a 250 mL bottle fitted with a sevoflurane-specific keyed filling adapter; no preservative, stabilizer, or diluent is added. Before loading into out-of-circuit precision vaporizers, the API is controlled against the USP Sevoflurane monograph for assay and related substances, and residual solvent limits are reviewed under VICH GL18 and ICH Q3C(R8). Clinical output in healthy dogs is anchored to a published minimum alveolar concentration of 2.36 vol%; delivery is typically maintained at 2.1–2.5 vol% inspired concentration, with induction via a tight-fitting mask or chamber at 4.0–5.0 vol% for no more than 3–5 min to limit dose-dependent vasodilation and hypotension. Feline patients, with a published MAC of 2.58 vol%, are maintained at 2.4–2.6 vol%; patients under 3 kg body mass require vaporizer adjustment in 0.25 vol% increments because small circuit volume magnifies vapour concentration errors. The terminal clinical product is balanced surgical anaesthesia with a recovery window of 5–10 min after the vaporizer is turned off. The primary process limit in this application is the use of a sevoflurane-calibrated vaporizer; substituting an isoflurane-calibrated unit introduces dosing error because saturated vapor pressure at 20 °C is approximately 21.3 kPa for sevoflurane, whereas isoflurane is higher by more than 10 kPa. Inhalant delivery through standard low-flow circle systems with fresh gas flow of 0.8–3.0 L/min must be stopped if the carbon dioxide absorbent canister surface temperature remains above 45 °C after the first 20 min; this condition accelerates base-catalyzed degradation of sevoflurane in desiccated absorbent.

When Low Fresh Gas Flow and Soda Lime Temperature Shift Compound A Kinetics in Equine Anaesthesia

In the equine circle circuit, low fresh gas flow is maintained to reduce agent consumption in animals with body masses above 400 kg, but this shifts the trajectory of Compound A formation in the absorbent canister. Published equine MAC of 2.31 vol% supports maintenance vaporizer settings of 2.0–2.8 vol% after injectable induction; mask induction alone is rarely used because of prolonged excitement and airway contamination. The terminal product is inhalant maintenance during field or hospital procedures such as castration, colic laparotomy, abscess drainage, and arthroscopy. The clean-air requirement is a sevoflurane-specific out-of-circuit vaporizer placed downstream of the oxygen flowmeter and upstream of the one-way inspiratory valve. Circle fresh gas flows below 1.0 L/min in a 500 kg horse create absorbent canister temperatures above 40 °C, especially when the water content of soda lime falls below 14% w/w. Under these conditions, sevoflurane can undergo alkaline degradation to fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether, designated Compound A, at concentrations that increase with lower flow, higher absorbent temperature, and use of baralyme instead of soda lime. The operational boundary is to maintain fresh gas flow of at least 1.5 L/min during low-flow maintenance, replace desiccated absorbent before connection, and avoid forced-air warming of the canister. The anesthetic workstation must comply with ISO 80601-2-13:2018 essential performance requirements for vapor concentration accuracy, alarm functions, and gas scavenging; line-lock fittings and keyed fill nozzles prevent accidental transfer to an isoflurane vaporizer. Recovery is prolonged relative to small animals because of peripheral tissue equilibration, and the final return to sternal recumbency is usually not attempted until the end-tidal sevoflurane concentration has fallen below 1.0 vol% and protective airway reflexes have returned.

Calibrated vaporizer output stability below 0.5 vol% is the controlling variable in rodent and rabbit laboratory anaesthesia, where body mass ranges from 20 g mice to 5 kg rabbits. The terminal product form is an induction chamber or nose-cone circuit supplied from a sevoflurane vaporizer, typically with an active scavenging interface to keep the room concentration below the 2 ppm NIOSH recommended ceiling. Published laboratory rodent procedures commonly use induction at 4.0–5.0 vol% carrier gas and maintenance at 1.5–2.5 vol%; the low blood-gas partition coefficient of 0.69 at 37 °C permits fast depth changes but also allows sudden awakening if the vaporizer output drifts by more than 0.2 vol%. The process is constrained by chamber wash-in kinetics: a non-rebreathing induction chamber of 20 L volume reaches target concentration only after 3–5 chamber volume turnovers, so timer-controlled protocols should not be shortened below this interval. Chamber materials and elastomer seals must be inspected for swelling or weight change after repeated exposure to undiluted sevoflurane vapor; glass and fluoropolymer components are preferred. Terminal endpoints are surgical anaesthesia for instrumented procedures, blood collection, and imaging, followed by recovery in a heated enclosure with no residual agent. Published data for strain-specific MAC values in laboratory rodents is limited; dosing is commonly titrated against righting reflex, respiratory rate, and pedal withdrawal rather than against a single fixed dial setting. Institutional animal care standards and local permitting govern the allowable vaporizer concentration and scavenging efficiency; no solid oral dosage form is used in this segment.

Why Avian and Exotic Species Require Vapor Delivery Resolution Below 0.25 vol% Increments

Avian and exotic animal patients with body masses from 30 g finches to 3 kg snakes have pulmonary and cardiovascular dynamics that amplify vaporizer setting errors. The terminal product is a low-dead-space T-piece or non-rebreathing circuit with a precision out-of-circuit vaporizer marked in 0.25 vol% increments or finer; standard large-animal circle circuits are not suitable because the one-way valve disc inertia and circuit volume delay induction and create excessive mechanical dead space. Psittacine birds are commonly induced in a clear plastic induction chamber at 4.0–5.0 vol% and maintained at 2.5–3.5 vol% after endotracheal intubation or mask adaptation, but published data for specific avian MAC values is limited and interspecies variation is wide. Reptiles absorb sevoflurane from the vascular spaces associated with the trachea and simple lungs, yet the onset is slower than in mammals; the vaporizer setting is held at the higher end of 3.0–4.0 vol% for the first 10–15 min in some species, then reduced to 1.5–2.5 vol% for maintenance. The critical operational limit is the accuracy of the vaporizer at low settings: a dial error of +0.25 vol% in a 100 g bird is pharmacologically larger than the same absolute error in a 500 kg horse because of minute ventilation scaling and low body mass. Fresh gas flow is typically set between 0.5 L/min and 1.5 L/min to maintain chamber oxygen above 40% and to accelerate washout of exhaled carbon dioxide. Terminal procedures include beak trimming, wound debridement, diagnostic imaging, and orthopedic fixation in small psittacines and reptiles; recovery is terminated only after spontaneous head righting and return of withdrawal reflexes. This segment has no viable tablet, capsule, or premix form, and injectable anaesthesia is not a recognized sevoflurane product configuration.

Portable field anaesthesia systems used in non-domestic species are built around a draw-over or push-over precision vaporizer connected to a compressed oxygen cylinder and a lightweight circle or demand valve. The terminal product is inhalation anaesthesia for free-ranging or captive wildlife such as small felids, canids, mustelids, and ungulates under 80 kg body mass, where capture is usually accomplished with injectable ketamine-alpha-2 agonist combinations before sevoflurane is introduced. Vaporizer settings are extrapolated from domestic surrogate MAC values: 2.0–2.5 vol% for maintenance in most carnivores, with induction through a face mask or endotracheal tube after injectable loading. Fresh gas flow in the field is commonly 1.0–2.0 L/min to balance oxygen consumption against cylinder mass; lower flows are permissible only when a soda lime canister with known moisture content is carried. The primary field-specific failure mode is condensation of sevoflurane in the outlet hose and pooling of dense vapor when ambient temperature drops below 10 °C; the vaporizer outlet and patient circuit should be insulated or warmed to maintain liquid-vapor equilibrium. Published data for this specific configuration is limited for many non-domestic species, so terminal dosing is adjusted using respiratory rate, palpebral reflex, and end-tidal CO₂ rather than a single fixed MAC. Occupational exposure in enclosed field stations must remain below the 2 ppm NIOSH recommended ceiling through active scavenging or open-air operation; no solid premix or drinking-water formulation is used because sevoflurane evaporates from open vehicles at ambient poultry and hoofstock housing temperatures.

Bulk Transfer and Filling of 100% Sevoflurane into Veterinary Anaesthetic Solutions Under GMP

Filling of 100% w/w sevoflurane veterinary inhalation solution from bulk API containers into 250 mL primary glass bottles is treated as a low-moisture, closed-transfer process under ICH Q7 Good Manufacturing Practice. The compound has a boiling point of 58.5 °C and a saturated vapor pressure of approximately 21.3 kPa at 20 °C; therefore the fill room is controlled to 15–20 °C and the transfer loop is closed with nitrogen overlay to reduce evaporative loss and to keep the time-weighted area concentration below 2 ppm. Stainless steel 316L transfer lines, PTFE gaskets, and low-dead-space diaphragm pumps are used; copper, zinc, and aluminium alloys are excluded from product-contact surfaces because surface compatibility data for fluorinated ethers under warm acidic conditions is limited and Lewis-acidic metal halides represent a known degradation risk class. The terminal product is a clear, colourless, non-stabilized volatile liquid labelled as a veterinary inhalant; no preservative, antioxidant, or carrier solvent is present. Release testing includes assay by capillary GC-FID against the USP Sevoflurane monograph, residual solvents under VICH GL18 and ICH Q3C(R8), and moisture by Karl Fischer titration under USP Chapter 921. Vaporizer-specific compatibility is part of the terminal product specification: the bottle neck must accept only the sevoflurane-specific keyed filler adapter, and adapter leak rate is controlled under packaging validation to prevent vapor release during repeated connection cycles. The filling process is the only mainstream downstream manufacturing route for sevoflurane API; subsequent terminal dosage forms are constituted at the point of use as vapour diluted in oxygen or air, not as liquid injection or enteral preparation.

A critical boundary appears when sevoflurane is assessed for tablets, capsules, powders, granules, or premix formulations. No compendial monograph or published industrial process describes sevoflurane as a solid oral veterinary dosage ingredient, because the drug has a boiling point of 58.5 °C and a vapor pressure above 20 kPa at 20 °C. Direct compression, wet granulation, and powder blending processes occur at ambient or elevated temperatures above 25 °C; under these conditions sevoflurane evaporates from the powder mass before a stable tablet or capsule granule can be formed. Any theoretical dry granulation would require jacketed, vapor-tight containment at or below 4 °C, residence times shorter than the evaporative loss threshold, and dedicated dust-control systems that are not described in VICH GL3 stability guidance or ICH Q7 process validation examples. The same limitation applies to feed premixes and drinking-water solutions: sevoflurane is not miscible with water, separates rapidly at ambient temperature, and produces an uncontrolled vapor phase in open mixing vessels or feed bins. Injectable dosage forms are equally unsuitable; liquid sevoflurane is formulated as a pure volatile liquid and is not diluted with aqueous vehicles, and a parenteral vial would require headspace pressure management that is incompatible with standard steam-sterilized or aseptically filled aqueous injections. Published data for sevoflurane in tablet, capsule, powder, granule, premix, and injection configurations is limited to absence of compendial recognition, not to clinical suitability. The only technically supported terminal product form in the listed set is the 100% w/w inhalation solution; all solid and aqueous enteral or parenteral forms are therefore outside the validated application boundary for sevoflurane veterinary-grade API.